Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use

详细信息    查看全文

• 作者：Deepak Voora MD^a ; ^b ; ^{deepak.voora@duke.edu"" rel=""nofollow} ; John Horton MS^b ; Svati H. Shah MD ; MHS^b ; ^c ; Linda K. Shaw MS^b ; L. Kristin Newby MD ; MHS^b
• 刊名：American Heart Journal
• 出版年：2011
• 出版时间：July 2011
• 年：2011
• 卷：162
• 期：1
• 页码：166-172.e1
• 全文大小：163 K

文摘

Background

We hypothesized that single-nucleotide polymorphisms (SNPs) associated with heightened in vitro platelet function during aspirin exposure (which we define as “laboratory aspirin resistance”) would be associated with greater risk for death, myocardial infarction (MI) or stroke among patients with coronary artery disease regularly using aspirin.

Methods

Duke Databank for Cardiovascular Disease patients with (n = 3,449, CATHeterization GENetics cohort) or without (n = 11,754, nongenetic cohort) banked DNA with ≥1 coronary stenosis >75 % were followed up at 6 months, then annually for death, MI, or stroke occurring during periods of reported aspirin use. We evaluated associations of candidate SNPs from GNB3, PEAR1, ITGB3, VAV3, ITGA2, GPVI, PTGS1, F2R, THBS1, A2AR, and GP1BA with events during follow-up using Cox proportional hazards modeling adjusted for clinical characteristics associated with outcomes in the nongenetic cohort.

Results

Over a median of 3.5 years, 2,762 (24 % ) nongenetic cohort patients and 648 (19 % ) CATHeterization GENetics cohort patients had the composite outcome during reported aspirin use. No candidate SNPs were significantly associated with death, MI, or stroke in either univariable or multivariable analyses. A prospective analysis demonstrated 80 % to 88 % power to detect a hazard ratio of ≥1.3 for minor allele carriers.

Conclusion

Patients with angiographically significant coronary artery disease regularly using aspirin and carrying SNPs associated with laboratory aspirin resistance were not at higher risk for death, MI, or stroke. Using these SNPs to guide more aggressive antiplatelet therapy is not justified by these results. Direct extrapolation from in vitro findings to the clinical setting should be avoided.